TG Therapeutics, Inc. $TGTX Shares Sold by WINTON GROUP Ltd

Key Points

• WINTON GROUP Ltd cut its TG Therapeutics stake by 57.4% in the second quarter, selling 21,146 shares and retaining 15,677 shares worth approximately $861,000. Institutional investors and hedge funds collectively own 58.58% of the company.
• Analyst sentiment is mixed: five analysts rate TGTX a Buy, two recommend Hold, and two rate it Sell. The consensus rating is Hold, with an average price target of $63 versus the stock’s reported price of $54.
• TG Therapeutics reported second-quarter revenue of $240.34 million, up 70.2% year over year and above estimates, but earnings of $0.05 per share missed the $0.31 consensus. The company’s shares recently traded near $54, below their 52-week high of $59.30.

WINTON GROUP Ltd reduced its stake in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 57.4% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 15,677 shares of the biopharmaceutical company's stock after selling 21,146 shares during the period. WINTON GROUP Ltd's holdings in TG Therapeutics were worth $861,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in TGTX. Engineers Gate Manager LP acquired a new position in shares of TG Therapeutics during the second quarter worth about $589,000. NewEdge Advisors LLC raised its holdings in shares of TG Therapeutics by 15.3% during the 2nd quarter. NewEdge Advisors LLC now owns 10,103 shares of the biopharmaceutical company's stock valued at $555,000 after buying an additional 1,343 shares during the period. IFP Advisors Inc lifted its position in TG Therapeutics by 1.3% during the 2nd quarter. IFP Advisors Inc now owns 209,318 shares of the biopharmaceutical company's stock worth $11,500,000 after acquiring an additional 2,780 shares in the last quarter. Allworth Financial LP lifted its position in TG Therapeutics by 99.7% during the 2nd quarter. Allworth Financial LP now owns 2,321 shares of the biopharmaceutical company's stock worth $128,000 after acquiring an additional 1,159 shares in the last quarter. Finally, Edge Wealth Management LLC acquired a new position in TG Therapeutics during the 2nd quarter worth approximately $275,000. 58.58% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts have issued reports on TGTX shares. JPMorgan Chase & Co. increased their price objective on shares of TG Therapeutics from $65.00 to $72.00 and gave the company an "overweight" rating in a research report on Friday, August 7th. B. Riley Financial lifted their price objective on shares of TG Therapeutics from $55.00 to $86.00 and gave the company a "buy" rating in a research note on Monday, July 27th. Bank of America boosted their target price on shares of TG Therapeutics from $17.00 to $20.00 and gave the stock an "underperform" rating in a research report on Tuesday, July 7th. Zacks Research downgraded shares of TG Therapeutics from a "hold" rating to a "strong sell" rating in a research note on Monday, September 7th. Finally, Weiss Ratings reaffirmed a "hold (c+)" rating on shares of TG Therapeutics in a report on Wednesday, July 29th. Five equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have assigned a Sell rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and an average target price of $63.00.

TG Therapeutics Trading Up 0.2%

NASDAQ:TGTX opened at $54.00 on Tuesday. The stock has a market cap of $8.27 billion, a price-to-earnings ratio of 19.71, a price-to-earnings-growth ratio of 2.31 and a beta of 1.67. TG Therapeutics, Inc. has a one year low of $26.76 and a one year high of $59.30. The company has a debt-to-equity ratio of 1.23, a quick ratio of 3.72 and a current ratio of 4.27. The business's 50-day simple moving average is $53.61 and its 200 day simple moving average is $43.94.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last issued its quarterly earnings data on Monday, August 3rd. The biopharmaceutical company reported $0.05 earnings per share for the quarter, missing analysts' consensus estimates of $0.31 by ($0.26). TG Therapeutics had a net margin of 55.22% and a return on equity of 73.49%. The business had revenue of $240.34 million for the quarter, compared to analyst estimates of $229.77 million. During the same quarter last year, the business earned $0.17 EPS. TG Therapeutics's revenue for the quarter was up 70.2% compared to the same quarter last year. As a group, sell-side analysts predict that TG Therapeutics, Inc. will post 0.92 earnings per share for the current fiscal year.

Insider Activity at TG Therapeutics

In other news, Director Laurence Charney sold 5,000 shares of the stock in a transaction that occurred on Thursday, September 10th. The stock was sold at an average price of $54.96, for a total transaction of $274,800.00. Following the completion of the transaction, the director directly owned 168,640 shares in the company, valued at approximately $9,268,454.40. This represents a 2.88% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Company insiders own 8.87% of the company's stock.

About TG Therapeutics

TG Therapeutics, Inc is a commercial-stage biopharmaceutical company focused on developing and delivering treatments for B-cell diseases and autoimmune disorders. The company's research and development programs are centered on therapies that target B cells, which play an important role in several immune-mediated conditions.

TG Therapeutics' principal product is BRIUMVI (ublituximab-xiiy), an anti-CD20 monoclonal antibody approved by the U.S. Food and Drug Administration for the treatment of adults with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting multiple sclerosis and active secondary progressive multiple sclerosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.